Cross-sectional seroprevalence of antibodies against 6, 11, 16 and 18 human papilloma virus (HPV) types among teenagers and young women in Italy by Lupi, Silvia et al.
O
r
ig
in
a
l
 a
r
t
ic
l
e
s
 a
n
d
 r
e
v
ie
w
s
171
Key words
• human papilloma virus
• seroprevalence
• adolescents
• young adults
Address for correspondence: Silvia Lupi, Dipartimento di Scienze Mediche, Sezione di Medicina di Sanità Pubblica, Università degli Studi di Ferrara, 
Ferrara, Italy. Email: silvia.lupi@unife.it. 
Silvia Lupi(a), Mauro Bergamini(a), Enrica Guidi(a), Pasquale Gregorio(a, b) 
and HPV Collaborative Group*
Cross-sectional seroprevalence 
of antibodies against 6, 11, 16 and 18 
human papilloma virus (HPV) types among 
teenagers and young women in Italy
(a) Dipartimento di Scienze Mediche, Sezione di Medicina di Sanità Pubblica, Università degli Studi di Ferrara, 
Ferrara, Italy
(b) Scuola di Specializzazione in Igiene e Medicina Preventiva, Università degli Studi di Ferrara, Ferrara, Italy
* the members of the HPV Collaborative Group are listed before the References
Ann Ist Super Sanità 2014 | Vol. 50, No. 2: 171-177
DOI: 10.4415/ANN_14_02_11
Abstract 
Background. Little is known about human papilloma virus (HPV) seroprevalence in the 
healthy Italian population. The aim of the study was to assess seroprevalence of antibodies 
against HPV 6, 11, 16 and 18 among girls and young women in Italy. 
Methods. Sera were tested with a commercially available ELISA assay detecting specific IgG. 
Results. Seroprevalence was 54.1% in girls between 11 to 18 years old and 8.2% in over 
18s. Overall seropositivity in birth cohorts invited for free immunization reached 72.8% and 
was significantly higher than in other age subgroups. The highest levels of antibodies were 
detected in girls of 12 years old that should have just completed the vaccination schedule. 
Conclusion. A standardized seroepidemiological survey on HPV represents a useful tool 
for identifying groups at risk in which immunization is recommended, monitoring of 
vaccinated women, assessing whether booster vaccination is required.
INTRODUCTION 
Public health is required to notice and adopt innova-
tive tools to ensure the best practices in disease pre-
vention. In the field of cervical cancer prevention, or-
ganized and opportunistic screening programmes have 
been very successful succeeding in reducing incidence 
of the disease in many developed countries. The behav-
iour of women, however, besides the limitations of the 
test itself, did not consent to date to eliminate all cases 
of disease. Recent release of two vaccines against hu-
man papilloma virus (HPV) gave rise to many expec-
tations in primary prevention. At the present over 100 
of HPV genotypes have been identified: some strains, 
defined low-risk types, like HPV 6 or 11, lead to genital 
warts while others, considered high-risk types, like HPV 
16 or 18 or 45, are implicated in lesions that promote 
the development of cervical cancer [1, 2]. Oncogenic 
HPV types are also involved in vulva, vagina, anus, pe-
nis, oral cavity, pharynx, and larynx cancers [3]. 
Dealing with one of the most common sexually trans-
mitted infections worldwide, frequently many young 
women and men become rapidly infected after first 
intercourse. The consistent use of a condom achieves 
only partial protection [4]. During their lifetime, a large 
part of women can become infected several times, but 
usually with different strains. Age-specific distribution 
of HPV infection presents a first peak in younger ages 
(before 25 years old), just after the onset of sexual rela-
tions, in all regions of the world, and a second one in 
perimenopausal ages, more clearly evident in the Amer-
icas, Africa and Europe [5]. Most infections are sub-
clinical and transient and when cervical samples are col-
lected, they may show the presence of HPV-DNA and 
mild cervical intraepithelial lesions. In more than 90% 
of women the viral DNA and the low-grade colposcopi-
cally detectable lesions disappear within one-two years 
due to cell-mediated immunity, not always associated to 
seroconversion [6, 7]. Although many infections clear 
with time, unfortunately a minority of women (10-15%) 
do not produce a successful immune response and they 
remain HPV-DNA positive with a stable viral infection 
[8, 9]. Women persistently infected with high risk HPV 
strains are at risk of the development of high grade cer-
vical intraepithelial neoplasia (CIN) and invasive cer-
vical cancer (CC). All cases of CC are attributable to 
persistent HPV infections, leading to the conclusion 
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that it is a necessary, but not a sufficient, cause of the 
disease [10, 11].
Cervical cancer is, worldwide, the third most com-
mon malignancy in women and the seventh overall with 
an estimated 530 000 new cases in 2008. More than 
85% of the global burden occurs in developing coun-
tries, where it accounts for 13% of all female cancers 
[12]. In Italy estimates indicate a total of 3418 new 
cases diagnosed every year with an incidence rate of 9.8 
new cases per 100 000 females, remaining a consider-
able cause of morbidity and mortality causing approxi-
mately 1000 deaths yearly [13].
The development of cervical cancer is a long process, 
leading to pre-cancerous lesions but the progression of 
disease can be modified through early detection and 
treatment of cytological abnormalities by established 
practice of periodical Pap test. Almost all Italian re-
gions have implemented screening programmes based 
on cervical smear. According to PASSI study 2011, fol-
lowing organized programmes and spontaneous activ-
ity, 73% of women between 25-64 years-old have had a 
Pap smear performed in the previous 3 years [14].
Cervical cytology analysis is a highly effective and 
established practice in many developed countries but 
HPV-DNA testing has consistently been shown to be 
superior in terms of sensitivity and positive predictive 
value. Screening protocols will therefore necessarily 
change and, in near future, HPV-DNA detection and 
Pap test will be closely associated [15].
Recent release and implementation of two prophylac-
tic HPV vaccines (the bivalent against high-risk types 
16 and 18 and the quadrivalent directed also against 6 
and 11 low-risk types) will similarly lead to revise the at-
titude of preventing cervical cancer. HPV is particularly 
effective in eluding detection by the immune system 
while during virus replication there is no cell damage 
or necrosis and subsequently absence of inflammation. 
The lack of viraemic phase contributes to the genera-
tion of a weak and inconsistent immune response [16]. 
Clinical trials evaluating existing vaccines were primar-
ily designed to demonstrate as efficacy endpoint the 
prevention of incident vaccine-related HPV infection 
and preneoplastic lesions caused by incident persistent 
infections related to vaccine HPV types. For immu-
nogenicity assessment, several methods were applied 
measuring different subsets of antibodies induced by 
vaccination with specific cut-off definitions, preclud-
ing direct comparison of serological data. To date no 
standardized serological assay method has been ac-
knowledged and no immune responses correlating with 
protection against infection or disease following subse-
quent natural exposure to HPV have been defined. It is 
well known that antibody levels induced by natural in-
fection do not protect against reinfection whereas titres 
elicited by immunization exceed 100-fold those arising 
from infection [17]. In Italy vaccination against HPV is 
offered free of charge to all girls in the twelfth year of 
life since 2008.
Data on immune status against HPV in a general 
healthy population are very limited. In this study, we 
investigated the presence of antibodies against HPV 6, 
11, 16, 18 types in a large sample of female popula-
tion living in Ferrara, a province of the Emilia-Romagna 
Region (North-East Italy), composed of teenagers and 
young women.
METHODS
Study population
Serum samples were collected at the laboratory analy-
sis of the S. Anna University Hospital of Ferrara from 
October to December 2011. At the end of routine 
analytical sessions, all tubes containing an adequate 
amount of surplus serum were selected and samples 
from children of both sexes from 1 to 10 years and fe-
male subjects aged 11 to 26 years were systematically 
harvested. All sera were rendered anonymous and were 
identified by a code. No additional information about 
vaccination against HPV, health status, use of drugs, 
lifestyle and sexual behaviour was gathered. Sera from 
immunocompromised individuals and repeat sera from 
the same individuals were excluded. Selected specimens 
were harvested in two aliquots which were stored at -20 
°C until analysis. The study protocol was approved by 
Local Ethics Committee.
HPV antibody detection 
Total anti-HPV immunoglobulin G (IgG) antibodies 
detection was performed by enzyme linked immuno-
sorbent assay ELISA using a commercial kit supplied by 
DRG Diagnostic GmbH (Germany). The plate micro-
wells were coated with virus-like particles derived from 
L1 protein of viral types 6, 11, 16 and 18 expressed in 
Saccharomyces cerevisiae. All the assays were performed 
solely with one lot of the ELISA kit within its declared 
shelf life period. After dilution 1:100, samples were 
analysed according to manufacturer’s recommenda-
tions using a continuous and automatic in line analysis 
device (BEP2000 Advance® System, Siemens Health-
care, Germany). According to the manufacturer’s in-
structions, cut-off value was defined as optical density 
(OD) of negative control plus 0.250. Seropositivity was 
defined as immune status ratio (ISR) parameter calcu-
lated as the ratio between sample OD and cut-off: a 
serum sample was considered positive if ISR value was 
≥1, if ISR value was <1 the sample was considered nega-
tive. For quantification of antibodies concentration (ex-
pressed as EU/ml) the ratio between sample OD and 
positive control OD multiplied by 100 was applied. The 
obtained parameter was suitable for expressing geomet-
rical mean titres (GMT). The concentration of positive 
control was set to be equal to 100 EU/ml.
Statistical methods 
All data were recorded in a database file using Micro-
soft Excel 2007. Seroprevalence data was summarized 
as percentages, and positive antibody titres were pre-
sented as geometric means. Differences between per-
centages were assessed by the Chi square test, whereas 
differences between geometric mean titres were as-
sessed by Student’s t-test of logarithmically transformed 
values. Statistical analysis was performed using Stat-
View® 5.0.1 software (Abacus Concepts, Berkeley, CA, 
USA). Statistical significance was set at p < 0.01 for all 
tests.
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RESULTS
A total of 798 sera were collected from a cross-section 
of subjects 1-26 years old divided into three groups, as 
summarized in Table 1, according to age: the control 
group was composed of 261 subjects of which 110 boys 
and 151 girls, aged between 1 and 10 years; the sec-
ond group consisted of 270 girls aged between 11 to 18 
years (mean age 15.2) and the last group included 267 
young women aged 19 to 26 years old (mean age 22.1). 
All samples belonging to the control group yielded no 
antibodies titres. On the whole, sera found to have 
HPV antibodies were 168. More than half (54.1%) of 
girls between 11 and 18 years were positive against a 
rate of 8.2% reported in the older age group. Seropreva-
lence against 6, 11, 16 and 18 HPV types was remark-
ably higher in teenagers than in young women with a 
statistically significant difference (p < 0.0001). 
The levels of total IgG anti-HPV are distributed in a 
rather wide range that varies from a minimum of about 
14.5 EU/ml in both groups to 130 EU/ml in older girls 
up to over 200 EU/ml in adolescents. Girls from 11 to 
18 years old showed a GMT of 68.9 EU/ml (95% CI, 
65.7-72.0 EU/ml) reaching values  of almost 2.5 times 
higher than in young women with a GMT of 29 EU/
ml (95% CI, 18.9-39.0 EU/ml), showing a statistically 
significant difference (p < 0.0001).
The trend of the antibody titres by single year of birth 
is shown in Figure 1: 11 year old girls have been exclud-
ed because, at the time of the serum collection, they 
represented the cohort being actively called for HPV 
immunization without having yet received all scheduled 
doses. The lowest concentration of immunoglobulin 
was detected in over 18s while the highest level was 
found in 12 year old girls. From 13 to 16 years, a de-
Presence of HPV antibodies
Age group (mean ± sd) Negative (ISR < 1)N (%)
Positive (ISR ≥ 1)
N (%)
Total
N (%)
1-10 years (5.4 ± 3.1) 261 (100.0) 0 (0.0) 261 (32.7)
11-18 years (15.2 ± 2.1) 124 (45.9) 146 (54.1) 270 (33.8)
19-26 years (22.1 ± 2.3) 245 (91.8) 22 (8.2) 267 (33.5)
Total 630 (78.9) 168 (21.1) 798 (100.0)
ISR: immune status ratio.
Table 1
Human papilloma virus (HPV) seroprevalence
Figure 1
Age-specific trends in anti-HPV IgG concentration.
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creasing tendency of anti-HPV IgG median titres has 
been evidenced, while at the same time, these birth co-
horts evidenced that single values  are distributed in a 
very wide range with peaks markedly elevated, whereas 
a slight increase was recovered in 17 year olds.
When considering seroprevalence and GMT of total 
IgG anti-HPV, the group of adolescents were further di-
vided into two subgroups based on membership to the 
birth cohorts covered by the active offer of anti-HPV 
vaccination (Table 2). Overall seropositivity considering 
young people invited for immunization (aged 12 to 15 
years) reached 72.8% compared to only 37.9% of girls 
aged 16-18 years (p < 0.0001). Teenagers showed an in-
creasing trend in seroprevalence, starting from over half 
of the 12 year old girls suddenly reaching more than 70% 
in following birth cohorts with a peak of 80% in 15 year 
old girls. These values  are comparable and consistent with 
data on vaccination coverage concerning the local health 
unit of Ferrara released by the Emilia-Romagna Region 
and updated to 31 December 2011 [18]. In following age 
groups, seroprevalence considerably decreased to 49% at 
16 and gradually reduced to 26.5% in 18 year old girls. 
In all birth cohorts of teenagers seroprevalence was con-
siderably higher compared to the over 18’s showing a sta-
tistically significant difference (p < 0.0001). The highest 
levels of total IgG anti-HPV (92.3 EU/ml) were detected 
in 12 year old girls who should have just completed 3 
doses of vaccination. GMT remained very elevated even 
in the next birth cohort but following values were found 
to progressively decrease with the exception of 17 year 
old girls that showed a value of 74.6 EU/ml. Statistical 
comparison has revealed a significant difference between 
each of the birth cohorts of adolescents and girls over 
18 (p < 0.0001 in all comparisons, except 18 year old-
over 18 p = 0.0037) and also when the two adolescents 
subgroups were separately compared with over 18 girls 
(p > 0.0001).
DISCUSSION
Seroepidemiological surveys on HPV have mainly 
considered illness conditions like several sites cancers 
and precancerous lesions [19-21] or particular popula-
tions considered at risk as HIV positive subjects, men 
having sex with men, sex workers [22-27]. The studies 
that took into consideration the general healthy popula-
tion [28-32] or the effect of immunization [33, 34] used 
various approaches and diverse methods. This makes it 
impossible to carry out comparisons of seroprevalence 
among age groups and countries. 
Previous investigations on HPV serology on Italian 
women have only considered pathological conditions, 
using a in-house ELISA method based on five recom-
binant HPV16 proteins. The first one [35] involved 
women with abnormal PAP smear and demonstrated 
that the assay was able to detect antibodies in patients 
infected with HPV16 and it was not genotype-specific 
as it could discover antibodies also in women infected 
by other genital HPVs. The same test was successfully 
applied in evaluating antibodies in HIV-positive women 
[24], showing that no significant correlation could be 
found between HPV DNA detection and seropositivity. 
The present study represents the first application of 
a standardized ELISA test able to assess antibody lev-
els against all HPV strains contained in the preparation 
of the quadrivalent vaccine. As reported in a survey on 
the Australian population [36], no cases of HPV sero-
positivity were detected in children above 10 years of 
age. Teenagers showed seroprevalence rates and anti-
bodies titres considerably higher than young women. 
Unfortunately in absence of information about sexual 
behaviour and vaccination, this finding can only be 
assumed as the result of the extensive immunization, 
since in birth cohorts affected by the free offer of vac-
cine higher GMTs have been detected. The subsequent 
peak in seroprevalence recorded in 17 year-old girls may 
be put in relation with the beginning of sexual activity. 
Low seroprevalence rate and antibody titres in young 
women, on the contrary, may be the result of a drop 
below detection threshold in the absence of a persistent 
antigenic exposure in subjects with a previous natural 
infection. Long-term persistent HPV infection tends to 
yield polyclonal immunoglobulin G serological reactiv-
ity, which can be measured by using the ELISA tech-
nique based on type-specific virus-like particles (VLPs) 
as antigens [37]. Although the specificity of HPV VLP 
ELISA is reasonably adequate at over 90%, its sensitiv-
ity is relatively low [38]. According to a relatively recent 
study [39], intra- and inter-assay performance variation 
is difficult to control, especially in cohort studies that 
require the testing of specimens over extended peri-
ods. Being mindful of this, we set out to standardize 
the VLP ELISA protocol that we used in the present 
prevalence study.
The use of a commercially available technique, al-
though not able to discriminate antibodies produced 
by the single viral strain, that employs a well-known 
technique as the ELISA assay we adopted has several 
advantages: first, the ability to carry out the determi-
nation on a large number of samples; second, it is an 
easy-to-use technique which is suitable to automation 
and standardization; third, it does not require over-ex-
pensive investments; fourth, it provides the opportunity 
to reveal the immune status of the population and then 
Table 2
Serology results in positive samples by age
Age (years) Positive (ISR ≥ 1)(%)
EU/ml
GMT (95% CI)
12-15 72.8 74.7 (66.9-82.5)
12 55.6 92.3 (67.1-117.6)
13 72.7 85.8 (72.7-98.9)
14 74.3 69.2 (54.7-83.6)
15 80.0 66.6 (52.6-80.6)
16-18 37.9 61.6 (51.3-71.8)
16 49.0 60.5 (44.3-76.6)
17 37.5 74.6 (61.3-87.9)
18 26.5 53.5 (31.8-75.3)
Over 18 8.2 29.0 (18.9-39.0)
ISR: immune status ratio.
GMT: geometrical mean titres.
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to be able to follow over time, with repeated measure-
ments, the effects of vaccination campaigns, as well as 
of natural infection. 
HPV serology has not been used yet in the clinical 
setting because of the variety of techniques and bio-
logical limitations, moreover sensitivity is relatively low 
[38]. Most studies relied on the detection of HPV 
DNA demonstrated that mucosal DNA does not per-
sist in most persons after infection [40] and attempts 
to detect it are prone to sampling error. In contrast, the 
results of serological assays appear to better correlate 
with cumulative post-exposure than DNA-based ap-
proaches [41]. The implementation of a standardized 
and commercially available assay as the ELISA method 
we adopted would be certainly valuable in broadening 
knowledge on the natural spread of infection. Therefore 
a further study taking into account women belonging to 
older age groups as well as the male population aimed 
to describe HPV epidemiology and identify groups at 
greatest risk will be useful.
On the level of public health, a wide seroepidemio-
logical survey represents an important tool in guiding 
prevention programmes identifying best age groups for 
immunization because HPV exposure in a population 
may greatly differ depending on the sexual behaviour 
of its members and, in the future, will contribute to the 
monitoring of vaccinated women measuring the dura-
tion of vaccine induced-protection and would poten-
tially enable the assessment of whether booster vacci-
nations are required. Although many prevention strate-
gies are available for cervical cancer, continued public 
health efforts should be focused on increasing vaccine 
coverage in the target age groups and cervical cancer 
screening for women at appropriate intervals with suit-
able method, considering the need of additional evalu-
ation to ensure appropriate use of health resources, as 
the vaccinated women will become eligible for screen-
ing at a later date.
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